Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03069053
Other study ID # IRCCSPSMATTEO
Secondary ID
Status Completed
Phase N/A
First received February 22, 2017
Last updated February 25, 2017
Start date July 1, 2016
Est. completion date February 20, 2017

Study information

Verified date February 2017
Source IRCCS Policlinico S. Matteo
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

Objectives- to find out whether a correlation exists between denudation of urothelium and diagnosic delay in patients with BPS / IC, secondary aim was to search a correlation between impact of symptoms evaluated with ICSI-ICPI and number of comorbid conditions associated with BPS-IC.

Patients and Methods- Fifty-seven consecutive patients underwent cystoscopy under anaesthesia to classify those cases suspected of BPS/IC. As for the evaluation of the ICSI-ICPI scores we considered significant relevant values those ≥ 12. Patients underwent cystoscopy with hydrodistension under general (90%) or locoregional anaesthesia. Bladder biopsies were taken, including detrusor muscle, from those areas with the most apparent bladder wall lesions. All biopsies were then fixed in 4% formalin and sent to the Pathologist for examination.


Description:

Between 2005 and 2016, in our Department 57 consecutive patients underwent cystoscopy under anaesthesia to classify those cases suspected of BPS/IC. Patients reported long-lasting irritative bladder symptoms, including urgency, daytime frequency of seven or more episodes, nocturia, and pain in the lower abdomen, lower back, vagina or perineum during filling or after micturition. Alternative diagnoses such as urinary tract infection (UTI) were excluded. Confusable diseases were ruled out by thorough history, clinical examination, urine analysis and imaging.

By means of a detailed medical history we considered the time of symptom onset, frequency of micturitions, the presence of associated diseases. All patients were given the same questionnaire (O'Leary-Sant Interstitial Cystitis Symptom and Problem Index) (19), filled at the time of bladder biopsy.

As for the evaluation of the ICSI-ICPI scores we considered significant relevant values those ≥ 12.

All patients underwent cystoscopy with hydrodistension under general (90%) or locoregional anaesthesia. A rigid cystoscope with a Ch. 22 caliber was used, mannitol solution was used as filling fluid, and infusion height was 80 cm above the symphysis pubis. During filling the bladder was continuously inspected. At maximal capacity, distension was maintained until spontaneous filling stopped and maximum capacity was reached. At this point the bladder was drained and bladder walls and mucosa were closely examined . The bladder was then filled again at approximately half capacity, and at least three deep biopsies were taken, including detrusor muscle, from those areas with the most apparent bladder wall lesions.

All biopsies were then fixed in 4% formalin and sent to the Pathologist for examination. It was specifically asked to assess the presence of urothelial denudation, inflammatory infiltrate, counts of mast cells in the submucosa and detrusor, presence of intrafascicular fibrosis and submucosal bleeding. A cut-off of 28 mast cells / mm2 was used for the assessment of detrusor mastocytosis.

Morphologic Study Biopsy samples were cut in 5-μm-thick sections, then stained with the following reagents for morphologic evaluation: Hematoxylin-Eosin, Giemsa and Masson Tricromic Stain. This procedure was performed by automatic stainers (Leica, mod. ST5020 and mod. Autostainer™ XL).

In each biopsy the following parameters were evaluated, according to the recommendations reported by Hanno et al. (20) and reported in Table 1.

If the biopsy wasn't adequately sized (< 1 mm2-wide), we decided to evaluate the most reliable parameters, giving a N.V. (Not Valuable) response to the others.

Such parameters were single-blindly studied by two independent pathologists using optic microscopes (Nikon, mod. Eclipse™ E400 and mod. Eclipse™ CI) and discordant cases were then discussed jointly.

Immunohistochemical Studies Immunohistochemical reactions with Dako monoclonal antibody anti-Human Mast-cell Tryptase (Clone AA1; IgG1, Kappa), at 1:4000 dilution, were performed in order to highlight the mast-cell component of the inflammatory infiltrate, and then to quantify it. According to the protocol followed at the Laboratory of Immunohistochemistry of the Pathology Unit the automatic immunostainer Dako Omnis™ was used.

Evaluation of the Immunostainings

The reactions were evaluated using optic microscopes (Nikon, mod. Eclipse™ E400 and mod. Eclipse™ CI). The following parameters were studied:

- Number of mast-cells/mm2 of mucosa;

- Number of mast-cells/mm2 of submucosa;

- Number of mast-cells/mm2 of the detrusor layer. In order to obtain the highest accuracy, a single-blind evaluation was performed by two independent pathologists; discordant or uncertain cases were then discussed jointly.

All patients were evaluated retrospectively using patient files, they were given a score between 0 to 5 according to the presence of the following criteria (each criteria counting one point): pain, nocturia, a bladder capacity of 500 mL, glomerulations, or interfascicular fibrosis.


Recruitment information / eligibility

Status Completed
Enrollment 57
Est. completion date February 20, 2017
Est. primary completion date December 15, 2016
Accepts healthy volunteers No
Gender All
Age group 19 Years to 67 Years
Eligibility Inclusion Criteria:

- Patients reported long-lasting irritative bladder symptoms, including urgency, daytime frequency of seven or more episodes, nocturia, and pain in the lower abdomen, lower back, vagina or perineum during filling or after micturition.

Exclusion Criteria:

- Alternative diagnoses such as urinary tract infection (UTI) were excluded. Confusable diseases were ruled out by thorough history, clinical examination, urine analysis and imaging.

Study Design


Locations

Country Name City State
Italy Clinical Epidemiology and Biometric Unit, Fondazione IRCCS Policlinico San Matteo Pavia
Italy Histology and Pathology Service, Fondazione IRCCS Policlinico San Matteo Pavia
Italy Obstetric and Gynecological Clinic, Fondazione IRCCS Policlinico San Matteo Pavia
Italy Urology Department Fondazione IRCCS Policlinico San Matteo Pavia

Sponsors (1)

Lead Sponsor Collaborator
IRCCS Policlinico S. Matteo

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary correlation between denudation of urothelium and diagnosic delay to find out whether a correlation exists between denudation of urothelium and diagnosic delay in patients with BPS / IC 11 years
Secondary correlation between impact of symptoms evaluated with ICSI-ICPI and number of comorbid conditions associated with IC to search a correlation between impact of symptoms evaluated with ICSI-ICPI and number of comorbid conditions associated with IC 11 years
See also
  Status Clinical Trial Phase
Completed NCT04313972 - IC PaIN Trial: Interstitial Cystitis Pain Improvement With Naltrexone Phase 4
Recruiting NCT02868775 - A Study to Determine the Role of Toll-like Receptor-4 Expression in Patients With Interstitial Cystitis/Bladder Pain Syndrome N/A
Not yet recruiting NCT01410461 - Identifying Predictors of Treatment Success in Painful Bladder Syndrome N/A
Completed NCT01197261 - OXN PR vs Placebo in Opioid-naive Subjects Suffering From Severe Pain Due to Bladder Pain Syndrome (BPS) Phase 2
Completed NCT00150488 - URACYST® For the Treatment of GAG Deficient Interstitial Cystitis N/A
Completed NCT00672087 - Diagnostic Challenges in IC (and Male CPPS)
Completed NCT02232282 - Acupuncture for Female IC/PBSyndrome and Its Effect on the Urinary Microbiome: A Randomized Controlled Trial N/A
Completed NCT00775281 - Changes in Inflammatory and Contractile Protein Expression in Patients With Painful Bladder Syndrome/IC. N/A
Completed NCT05223244 - Bladder Capacity as Objective Measure of Intravesical Treatment of Newly Diagnosed IC Phase 4
Completed NCT02600715 - Reduction of Bladder Injection Pain With Belladonna Opiate Suppository Phase 4
Completed NCT02457182 - Mindfulness-Based Therapy for Interstitial Cystitis/Bladder Pain Syndrome N/A
Withdrawn NCT03027076 - Microbiome of Urologic Chronic Pelvic Pain Syndrome N/A
Completed NCT00434343 - Physical Therapy Trial for Pelvic Pain N/A
Terminated NCT03143920 - Hyperbaric Oxygen Therapy for Inflammatory Conditions of the Urinary Bladder Early Phase 1
Completed NCT02411110 - A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis/Bladder Pain Syndrome Phase 2
Completed NCT00903643 - Sensory Processing in Subjects With Painful Bladder Syndrome N/A
Completed NCT00194610 - Botox as a Treatment for Interstitial Cystitis in Women Phase 4
Recruiting NCT06299683 - Pain Type and Interstitial Cystitis/Bladder Pain Syndrome Treatment N/A
Terminated NCT04268810 - Prospective Trial Comparing Intravesical Chondroitin Sulphate 2% and DMSO in the Treatment of PBS/Interstitial Cystitis Phase 4
Completed NCT01294878 - Omalizumab in Interstitial Cystitis/Bladder Pain Syndrome Phase 3